Questions About Cancer? 1-800-4-CANCER

Childhood Astrocytomas Treatment (PDQ®)

Health Professional Version
Last Modified: 10/29/2014

Changes to this Summary (10/29/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Childhood Astrocytomas

Revised text to state that between 1975 and 2010, childhood cancer mortality decreased by more than 50% (cited Smith et al. as reference 3).

Added Bandopadhayay et al. as reference 52 and Mirow et al. as reference 56.

Treatment of Childhood High-Grade Astrocytomas

Revised text to state that the role of temozolomide given concurrently with radiation therapy for children with supratentorial high-grade glioma appears comparable to the outcome seen in children treated with nitrosourea-based therapy and again demonstrated an event-free survival advantage for those children without methylated O6-methylguanine-DNA-methyltransferase overexpression.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.